Teva Announces FDA Acceptance of Reslizumab For Asthma – Lung Disease News


Lung Disease News

Teva Announces FDA Acceptance of Reslizumab For Asthma
Lung Disease News
Reslizumab is being developed as treatment of inadequately controlled asthma in adults and young people who have increased blood eosinophils, despite being under treatment with an inhaled corticosteroid (ICS) drug regimen. “Despite currently available …
FDA to review Teva asthma biologicBioPharma Dive
FDA will review Teva's asthma biologic reslizumabPharmaTimes
Stock Update (NYSE:TEVA): Teva Pharmaceuticals Industries Ltd (ADR Smarter Analyst
PMLiVE
all 20 news articles »

View full post on asthma – Google News

Positive Results for Reslizumab in Asthma Trials – Monthly Prescribing Reference

Positive Results for Reslizumab in Asthma Trials
Monthly Prescribing Reference
Teva announced positive results from its Phase 3 studies of reslizumab in patients with uncontrolled moderate to severe asthma with elevated eosinophils, treated with standard of care therapies. Reslizumab is an investigational humanized monoclonal …
Teva's Asthma Drug 'Significantly' Improves Lung Function In Phase 3 TrialsNASDAQ

all 7 news articles »

View full post on asthma – Google News

Teva’s Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies – RTT News

Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies
RTT News
Teva Pharmaceutical Industries Ltd. (TEVA: Quote) announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma …

and more »

View full post on asthma – Google News

Teva’s Reslizumab Delivers Clinically and Statistically Significant Reduction … – Wall Street Journal

Teva's Reslizumab Delivers Clinically and Statistically Significant Reduction
Wall Street Journal
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma …

View full post on asthma – Google News